Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial

Authors

Amitkumar Mehta, University of Alabama, Birmingham
Leslie Popplewell, City of Hope Medical Center
Graham P Collins, Oxford University
Sonali M Smith, University of Chicago
Ian W Flinn, Sarah Cannon Research Institute at Tennessee Oncology
Nancy L Bartlett, Washington University School of Medicine in St. Louis
Nilanjan Ghosh, Wake Forest University
Gal Hacohen-Kleiman, Gilead Sciences, Inc
Yanan Huo, Gilead Sciences, Inc
Linda Su-Feher, Gilead Sciences, Inc
Camille Renard, Gilead Sciences, Inc
Ranjana Advani, Stanford University
Mark Roschewski, National Institutes of Health

Journal

Blood Advances

Publication Date

11-26-2024

Volume

8

Issue

22

First Page

5855

Last Page

5863

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2024013277

Rights and Permissions

Mehta A, Popplewell L, Collins GP, Smith SM, Flinn IW, Bartlett NL, Ghosh N, Hacohen-Kleiman G, Huo Y, Su-Feher L, Renard C, Advani R, Roschewski M. Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial. Blood Adv. 2024 Nov 26;8(22):5855-5863. doi: 10.1182/bloodadvances.2024013277. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.

Recommended Citation

Mehta, Amitkumar; Popplewell, Leslie; Collins, Graham P; Smith, Sonali M; Flinn, Ian W; Bartlett, Nancy L; Ghosh, Nilanjan; Hacohen-Kleiman, Gal; Huo, Yanan; Su-Feher, Linda; Renard, Camille; Advani, Ranjana; and Roschewski, Mark, "Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial." Blood Advances. 8, 22. 5855 - 5863. (2024).
https://digitalcommons.wustl.edu/oa_4/4547

Additional Links

Supplemental material is available for this article at publisher site.